Effect of siRNA‑induced inhibition of IL‑6 expression in rat cerebral gliocytes on cerebral edema following traumatic brain injury

Xu,Bin; Yu,Dong‑Ming; Liu,Fu‑Sheng

doi:10.3892/mmr.2014.2462

Effect of siRNA‑induced inhibition of IL‑6 expression in rat cerebral gliocytes on cerebral edema following traumatic brain injury

Authors:
- Bin Xu
- Dong‑Ming Yu
- Fu‑Sheng Liu
View Affiliations

Affiliations: Department of Emergency, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, P.R. China, Brain Tumor Research Center, Beijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, P.R. China
Published online on: August 7, 2014 https://doi.org/10.3892/mmr.2014.2462
Pages: 1863-1868

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the effect of RNA interference (RNAi) on the inhibition of interleukin (IL)‑6 expression in rat cerebral gliocytes in vitro and rat cerebral traumatic tissues in vivo, as well as the effect of RNAi on cerebral edema. pSUPER vectors containing IL‑6 small hairpin RNA (pSUPER‑IL‑6 1‑5) were designed, constructed and transfected into C6 rat glioma cells using cationic liposomes. ELISA was used to select the plasmid with the strongest interference effect. A freefall method was used to generate a rat brain injury model and rats were randomly divided into treatment, empty plasmid and control groups (n=14/group). IL‑6 levels, water content and sodium content were determined in the brain tissues at 24 and 72 h post‑injury. pSUPER‑IL‑6 was effectively transfected into C6 cells and was found to inhibit the expression of IL‑6 rather than IL‑8. The pSUPER‑IL‑6 1 vector was most effective in inducing RNAi. In vivo, IL‑6 levels were observed to be lowest in the interference group and there were statistically significant differences in water and sodium content among the experimental groups (P<0.05). RNAi was found to inhibit IL‑6 expression in vivo and in vitro in rat cerebral gliocytes, and the reduction of the IL‑6 levels was found to reduce post‑traumatic cerebral edema.

View Figures

View References

1	Dewall J: The ABCs of TBI. Evidence-based guidelines for adult traumatic brain injury care. JEMS. 35:54–61. 2010.PubMed/NCBI
2	Mustafa AG and Alshboul OA: Pathophysiology of traumatic brain injury. Neurosciences (Riyadh). 18:222–234. 2013.
3	Stein DM, Lindell A, Murdock KR, et al: Relationship of serum and cerebrospinal fluid biomarkers with intracranial hypertension and cerebral hypoperfusion after severe traumatic brain injury. J Trauma. 70:1096–1103. 2011. View Article : Google Scholar
4	Zhang R, Liu Y, Yan K, et al: Anti-inflammatory and immunomodulatory mechanisms of mesenchymal stem cell transplantation in experimental traumatic brain injury. J Neuroinflammation. 10:1062013. View Article : Google Scholar : PubMed/NCBI
5	Roberts DJ, Jenne CN, Léger C, et al: Association between the cerebral inflammatory and matrix metalloproteinase responses after severe traumatic brain injury in humans. J Neurotrauma. 30:1727–1736. 2013. View Article : Google Scholar
6	Yang SH, Gangidine M, Pritts TA, Goodman MD and Lentsch AB: Interleukin 6 mediates neuroinflammation and motor coordination deficits after mild traumatic brain injury and brief hypoxia in mice. Shock. 40:471–475. 2013. View Article : Google Scholar
7	Nakamura M, Okada S, Toyama Y and Okano H: Role of IL-6 in spinal cord injury in a mouse model. Clin Rev Allergy Immunol. 28:197–204. 2005. View Article : Google Scholar : PubMed/NCBI
8	Hildebrand F, Pape HC and Krettek C: The importance of cytokines in the posttraumatic inflammatory reaction. Unfallchirurg. 108:793–794. 796–803. 2005.(In German).
9	Poulsen CB, Penkowa M, Borup R, et al: Brain response to traumatic brain injury in wild-type and interleukin-6 knockout mice: a microarray analysis. J Neurochem. 92:417–432. 2005. View Article : Google Scholar : PubMed/NCBI
10	Van Wagoner NJ and Benveniste EN: Interleukin-6 expression and regulation in astrocytes. J Neuroimmunol. 100:124–139. 1999.PubMed/NCBI
11	Campo S, Serlupi-Crescenzi O, Arseni B, et al: Comparative activity of Sant7 and anti-IL-6, IL-6R monoclonal antibodies in a murine model of B-cell lymphoma. Cytokine. 31:368–374. 2005. View Article : Google Scholar : PubMed/NCBI
12	Srirangan S and Choy EH: The role of interleukin 6 in the pathophysiology of rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2:247–256. 2010. View Article : Google Scholar : PubMed/NCBI
13	Tuschl T, Zamore PD, Lehmann R, et al: Targeted mRNA degradation by double-stranded RNA in vitro. Genes Dev. 13:3191–3197. 1999. View Article : Google Scholar : PubMed/NCBI
14	Coelho T, Adams D, Silva A, et al: Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 369:819–829. 2013. View Article : Google Scholar : PubMed/NCBI
15	Brummelkamp TR, Bernards R and Agami R: A system for stable expression of short interfering RNAs in mammalian cells. Science. 296:550–553. 2002. View Article : Google Scholar : PubMed/NCBI
16	Feeney DM, Boyeson MG, Linn RT, Murray HM and Dail WG: Responses to cortical injury: I. Methodology and local effects of contusions in the rat. Brain Res. 211:67–77. 1981. View Article : Google Scholar : PubMed/NCBI
17	Bingham D, John CM, Panter SS and Jarvis GA: Post-injury treatment with lipopolysaccharide or lipooligosaccharide protects rat neuronal and glial cell cultures. Brain Res Bull. 85:403–409. 2011. View Article : Google Scholar : PubMed/NCBI
18	Spooren A, Kolmus K, Laureys G, et al: Interleukin-6, a mental cytokine. Brain Res Rev. 67:157–183. 2011. View Article : Google Scholar : PubMed/NCBI
19	Kotzerke K, Mempel M, Aung T, et al: Immunostimulatory activity of murine keratinocyte-derived exosomes. Exp Dermatol. 22:650–655. 2013. View Article : Google Scholar : PubMed/NCBI
20	Ziebell JM and Morganti-Kossmann MC: Involvement of pro- and anti-inflammatory cytokines and chemokines in the pathophysiology of traumatic brain injury. Neurotherapeutics. 7:22–30. 2010. View Article : Google Scholar : PubMed/NCBI
21	Lu J, Goh SJ, Tng PY, Deng YY, Ling EA and Moochhala S: Systemic inflammatory response following acute traumatic brain injury. Front Biosci (Landmark Ed). 14:3795–3813. 2009. View Article : Google Scholar : PubMed/NCBI
22	Frugier T, Morganti-Kossmann MC, O’Reilly D and McLean CA: In situ detection of inflammatory mediators in post mortem human brain tissue after traumatic injury. J Neurotrauma. 27:497–507. 2010. View Article : Google Scholar : PubMed/NCBI
23	Harhay MO, Tracy RP, Bagiella E, et al: Relationship of CRP, IL-6, and fibrinogen with right ventricular structure and function: the MESA-Right Ventricle Study. Int J Cardiol. 168:3818–3824. 2013. View Article : Google Scholar : PubMed/NCBI
24	Caselli C, D’Amico A, Caruso R, et al: Impact of normalization strategy on cardiac expression of pro-inflammatory cytokines: evaluation of reference genes in different human myocardial regions after Left Ventricular Assist Device support. Cytokine. 63:113–122. 2013. View Article : Google Scholar
25	Chiaretti A, Antonelli A, Mastrangelo A, et al: Interleukin-6 and nerve growth factor upregulation correlates with improved outcome in children with severe traumatic brain injury. J Neurotrauma. 25:225–234. 2008. View Article : Google Scholar : PubMed/NCBI
26	Woodcock T and Morganti-Kossmann MC: The role of markers of inflammation in traumatic brain injury. Front Neurol. 4:182013. View Article : Google Scholar : PubMed/NCBI
27	Papa L, Ramia MM, Kelly JM, Burks SS, Pawlowicz A and Berger RP: Systematic review of clinical research on biomarkers for pediatric traumatic brain injury. J Neurotrauma. 30:324–338. 2013. View Article : Google Scholar : PubMed/NCBI
28	Patterson ZR and Holahan MR: Understanding the neuroinflammatory response following concussion to develop treatment strategies. Front Cell Neurosci. 6:582012. View Article : Google Scholar : PubMed/NCBI
29	Erta M, Quintana A and Hidalgo J: Interleukin-6, a major cytokine in the central nervous system. Int J Biol Sci. 8:1254–1266. 2012. View Article : Google Scholar : PubMed/NCBI
30	Liu Y, Fuchs J, Li C and Lin J: IL-6, a risk factor for hepatocellular carcinoma: FLLL32 inhibits IL-6-induced STAT3 phosphorylation in human hepatocellular cancer cells. Cell Cycle. 9:3423–3427. 2010. View Article : Google Scholar : PubMed/NCBI
31	Mukaino M, Nakamura M, Yamada O, et al: Anti-IL-6-receptor antibody promotes repair of spinal cord injury by inducing microglia-dominant inflammation. Exp Neurol. 224:403–414. 2010. View Article : Google Scholar : PubMed/NCBI
32	Yang Z, Feng J, Li Y, Hu M, et al: Structure-based design and characterization of a Novel IL-6 antagonist peptide. Mol Immunol. 42:1015–1021. 2005. View Article : Google Scholar : PubMed/NCBI
33	Boos TL, Cheng K, Greiner E, Deschamps JR, Jacobson AE and Rice KC: Configurational reassignment and improved preparation of the competitive IL-6 receptor antagonist 20R,21R-epoxyresibufogenin-3-formate. J Nat Prod. 75:661–668. 2012. View Article : Google Scholar : PubMed/NCBI
34	Purohit A, Singh A, Ghilchik MW, Serlupi-Crescenzi O and Reed MJ: Inhibition of IL-6+IL-6 soluble receptor-stimulated aromatase activity by the IL-6 antagonist, Sant 7, in breast tissue-derived fibroblasts. Br J Cancer. 88:630–635. 2003. View Article : Google Scholar : PubMed/NCBI
35	Ekström M, Halle M, Bjessmo S, et al: Systemic inflammation activates the nuclear factor-kappaB regulatory pathway in adipose tissue. Am J Physiol Endocrinol Metab. 299:E234–E240. 2010.PubMed/NCBI
36	Israelsson C, Wang Y, Kylberg A, Pick CG, Hoffer BJ and Ebendal T: Closed head injury in a mouse model results in molecular changes indicating inflammatory responses. J Neurotrauma. 26:1307–1314. 2009. View Article : Google Scholar : PubMed/NCBI